ESMO 2021 | Neoadjuvant enoblituzumab for localized prostate cancer
Eugene Shenderov, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, discusses the preliminary safety and efficacy data from the Phase II trial (NCT02923180) of neoadjuvant enoblituzumab in men with localized prostate cancer. Patients with intermediate or high-grade Gleason scores received 6 doses of enoblituzumab, followed by a prostatectomy. Immune correlates from blood samples and pre- and post-treatment tissue were analyzed. Tolerability and prostate-specific antigen (PSA) responses were acceptable, with several patients having PSA-undetectable disease after 3 years. Additionally, the tumor microenvironment showed increased levels CD8 cytotoxic T cells and granzyme B post-treatment. Dr Shenderov hopes this research will help improve understanding of how to treat both localized and metastatic prostate cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Shenderov’s disclosures are as follows: founder and CEO of LifeImmune, Inc; has received clinical trial institutional research funding from MacroGenics, and has served as a consultant for Firstthought.io and Guidepoint Global.
